



**MANUFACTURER OF  
BULK DRUGS &  
IMPORTERS OF  
SOLVENTS & CHEMICALS**

H.O: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 ☎ : (022) 23455543 Email: [corporate@aareydrugs.com](mailto:corporate@aareydrugs.com)  
REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE ☎ (02525) 271049 Email: [info@aareydrugs.com](mailto:info@aareydrugs.com)  
CIN: L99999MH1990PLC056538

Date: 13<sup>th</sup> August, 2025

To,

<b>BSE Limited</b> The Manager, Corporate Service Department P.J. Towers, Dalal Street, Mumbai- 400 001  <b>Scrip Code: 524412</b>	<b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai – 400051  <b>NSE Symbol: AAREYDRUGS</b>
--	---

**Sub: Outcome of Board Meeting held on today i.e 13<sup>th</sup> August, 2025**

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company at its Meeting held today i.e. 13<sup>th</sup> August, 2025 have passed the following resolution.

1. The Board of Directors of the Company has considered and approved the Unaudited Financial Results for the quarter ended 30<sup>th</sup> June, 2025 along with the Limited Review Report, MD/CFO certification.

\*Company segment is single

The meeting was started at 04:00 p.m. and was concluded at 05:15 p.m

Kindly take the same on record.

Thanking you,

Yours Faithfully,

**For AAREY DRUGS & PHARMACEUTICALS LIMITED**

**Nimit R Ghatalia**  
**Director**  
**DIN: 07069841**

**Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended.**

To,

The Board of Directors

Aarey Drugs and Pharmaceuticals Limited

1. We have reviewed the accompanying statement of unaudited financial results of **Aarey Drugs and Pharmaceuticals Limited** ("the Company") for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the listing Regulations").
2. The Company's management is responsible for preparation of the statement in the accordance with the recognition and measurement and principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim financial reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Director. Our responsibility is to express conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



# MOTILAL & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

(A MEMBER FIRM OF M A R C K S NETWORK)



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Motilal & Associates LLP**

*(a member firm of M A R C K S Network)*

**Chartered Accountants**

ICAI FRN: 106584W/W100751

A handwritten signature in blue ink, appearing to read 'Rishabh M. Jain', with a horizontal line extending to the right.

**CA Rishabh M. Jain**

*Partner*

**Mem. No.: 179547**

**Place: Mumbai**



**Date: 13<sup>th</sup> August, 2025**

**UDIN: 25179547BMMBIZ9093**

**Aarey****DRUGS & PHARMACEUTICALS LTD.****MANUFACTURERS OF BULK DRUGS &  
DEALERS OF CHEMICAL & SOLVENTS**GST NO. : 27AAACA5253A1Z9  
CIN NO. : L99999MH1990PLC056538HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP. TELLIGALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA, TEL. : (022) 62872900/2999 E-mail : info@areydrugs.com  
REGD. OFFICE & FACTORY : E-34, M.I.D.C., TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL.: (02525) 622165 E-mail : works@areydrugs.com Web : www.areydrugs.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30TH JUNE, 2025				
(Rs. in Lakhs except EPS)				
Particulars	Quarter ended			Year Ended
	30.06.2025	31.03.2025	30.06.2024	31.03.2025
	Unaudited	Audited	Unaudited	Audited
Revenue from Operations	10,220.83	10,809.93	12,691.18	47,394.33
Other income	155.18	753.79	157.53	981.24
<b>TOTAL INCOME</b>	<b>10,376.00</b>	<b>11,563.72</b>	<b>12,848.71</b>	<b>48,375.57</b>
<b>EXPENSES</b>	<b>9,306.79</b>	<b>12,374.84</b>	<b>11,509.31</b>	<b>47,286.57</b>
Cost of Materials Consumed				
Changes in Inventories of Finished goods, Work in progress and Stock in trade	476.78	-1,457.24	850.15	-1,080.45
Employee Benefit Expenses	13.84	26.70	13.76	80.55
General Administrative Expense	16.95	35.84	17.02	97.46
Selling and Distribution Expense	39.89	97.76	42.59	239.11
Depreciation and Amortization Expense	48.83	40.80	46.58	194.49
Finance Cost	103.76	130.00	95.70	466.44
Other Expenses	196.33	152.52	140.53	481.21
<b>TOTAL EXPENSES</b>	<b>10,203.18</b>	<b>11,401.22</b>	<b>12,715.63</b>	<b>47,765.38</b>
<b>Profit Before Exceptional Items and Tax</b>	<b>172.82</b>	<b>162.50</b>	<b>133.08</b>	<b>610.19</b>
Exceptional Items	-	-	-	-
<b>Profit / (Loss) Before Tax</b>	<b>172.82</b>	<b>162.50</b>	<b>133.08</b>	<b>610.19</b>
<b>Tax Expenses</b>				
a) Short/(excess) provision of earlier years	35.00	50.67	10.00	50.67
b) Current Tax	0.69	60.00	-0.82	140.19
c) Deferred Tax	-	4.82	-	16.94
<b>Profit / (Loss) for the period from continuing operations</b>	<b>137.13</b>	<b>47.01</b>	<b>123.91</b>	<b>402.39</b>
Profit/(loss) from discontinued operations	-	-	-	-
Tax expense of discontinued operations	-	-	-	-
<b>Profit/(loss) from Discontinued operations (after tax)</b>	<b>137.13</b>	<b>47.01</b>	<b>123.91</b>	<b>402.39</b>
<b>Profit/(loss) for the period</b>	<b>137.13</b>	<b>47.01</b>	<b>123.91</b>	<b>402.39</b>
<b>Other Comprehensive Income</b>	<b>137.13</b>	<b>47.01</b>	<b>123.91</b>	<b>402.39</b>
<b>Total Comprehensive Income for the year</b>	<b>137.13</b>	<b>47.01</b>	<b>123.91</b>	<b>402.39</b>
<b>Earnings per equity share : (of Rs. 10/- each) (for the period/year): *</b>				
a) Basic EPS (Rs.)	0.48	0.17	0.44	1.42
b) Diluted EPS (Rs.)	0.48	0.17	0.44	1.42
<b>Number of Shares</b>	<b>28,454,303</b>	<b>28,454,303</b>	<b>28,054,303</b>	<b>28,454,303</b>
<b>Percentage of Shareholding</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>
<b>Paid-up Equity Share Capital (FV of Rs. 10/- each) (incl. forfeited shares)</b>	<b>2,845.43</b>	<b>2,845.43</b>	<b>2,805.43</b>	<b>2,845.43</b>

**\*Not Annualised**


- The above unaudited Financial results of the Company for the quarter ended 30th June, 2025 have been reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meetings held on 13th August, 2025.
- The aforesaid unaudited Financial results for the quarter ended 30th June, 2025 have been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 as prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of Regulation 33 and Regulation 52 of SEBI (Listing, Obligation and Disclosure Requirements) Regulations, 2015.
- The Company operates only in one segment in Manufacturing and Trading of Drugs & Pharmaceutical and all other allied activities revolving around the same. As such there is no other separate reportable segment as defined by IND AS 108 - "Operating Segments"
- The Figures of the previous year and/or period(s) have been regrouped wherever necessary.

By Order of the Board of Directors  
For Aarey Drugs and Pharmaceuticals LimitedMihir R. Ghatia  
Managing Director  
DIN: 00581005Date: 13th August, 2025  
Place: Mumbai

**Certificate of Managing Director (MD)**

I, Mihir R. Ghatalia, Managing Director (MD) of Aarey Drugs & Pharmaceuticals Ltd., certify;

- 1) That I have reviewed the Unaudited Financial Statements for the quarter ended 30<sup>th</sup> June, 2025 and to the best of my knowledge and belief:
  - a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and
  - b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.
- 2) That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.
- 3) That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.



**Mihir R. Ghatalia**

**MD**

**Date: 13/08/2025**

**Place: Mumbai**



**Certificate of Chief Financial Officer (CFO)**

I, Mira R. Ghatalia, Chief Financial Officer (CFO) of Aarey Drugs & Pharmaceuticals Ltd., certify;

- 1) That I have reviewed the Unaudited Financial Statements for the quarter ended 30<sup>th</sup> June, 2025 and to the best of my knowledge and belief:
  - a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and
  - b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.
- 2) That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.
- 3) That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.



**Mira M. Ghatalia**  
**CFO**

**Date: 13/08/2025**

**Place: Mumbai**